tetano
Editor, Senior Moderator
Virol Sin
. 2020 Jul 23.
doi: 10.1007/s12250-020-00270-x. Online ahead of print.
Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity
Wen-Hua Kong[SUP] 1 [/SUP], Rong Zhao[SUP] 2 [/SUP], Jun-Bo Zhou[SUP] 1 [/SUP], Fang Wang[SUP] 1 [/SUP], De-Guang Kong[SUP] 1 [/SUP], Jian-Bin Sun[SUP] 2 [/SUP], Qiong-Fang Ruan[SUP] 2 [/SUP], Man-Qing Liu[SUP] 3 [/SUP]
Affiliations
Abstract
The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17-83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.
Keywords: COVID-19; Chemiluminescence immunoassay (CLIA); Nucleic acid test (NAT); Real-time polymerase chain reaction (RT-PCT); Serologic test.
. 2020 Jul 23.
doi: 10.1007/s12250-020-00270-x. Online ahead of print.
Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity
Wen-Hua Kong[SUP] 1 [/SUP], Rong Zhao[SUP] 2 [/SUP], Jun-Bo Zhou[SUP] 1 [/SUP], Fang Wang[SUP] 1 [/SUP], De-Guang Kong[SUP] 1 [/SUP], Jian-Bin Sun[SUP] 2 [/SUP], Qiong-Fang Ruan[SUP] 2 [/SUP], Man-Qing Liu[SUP] 3 [/SUP]
Affiliations
- PMID: 32705575
- DOI: 10.1007/s12250-020-00270-x
Abstract
The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17-83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity.
Keywords: COVID-19; Chemiluminescence immunoassay (CLIA); Nucleic acid test (NAT); Real-time polymerase chain reaction (RT-PCT); Serologic test.